Pulmonary arterial hypertension (PAH) is a rare form of pulmonary hypertension. It occurs because progressive vascular ...

A recent publication in the International Journal of Cardiology , Pulmonary artery denervation in pulmonary hypertension: A ...

according to a poster presented at the Pulmonary Vascular Research Institute 2025 Annual Congress. In this series, we dive into what rheumatologists should know about pulmonary hypertension ...

The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) ...

A recent publication in the International Journal of Cardiology, Pulmonary artery denervation in pulmonary hypertension: A comprehensive meta-analysis, has shed light on the potential of pulmonary ...

Pulmonary arterial hypertension is caused by narrowing of the blood vessels in the lungs. Learn how it happens, including ...

In April 2025, Actelion announced a study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the ...

The new drug sotatercept stops the remodelling of the pulmonary vessels and even helps patients with advanced pulmonary arterial hypertension (PAH) who have not yet been treated.

Pulmonary hypertension is a common consequence of interstitial lung disease (PH-ILD), with the highest rate seen among ...

PAH is a rare and progressive disease characterised by increased pulmonary vascular resistance, ultimately leading to right ...

Exo unveils its 10 th FDA-cleared AI, delivering instant, on-device Global Longitudinal Strain (GLS) analysis — no cloud, no ...